Professor Samreen Ahmed, Dr Raffaele Califano, Dr David Farrugia and CNS, Gemma Shaw review the 5-year data for dabrafenib + trametinib in NSCLC and discuss key learning from their clinical experience of this targeted combination through sharing patient case studies.
“As with the molecular non-small lung cancer paradigm, if we have an actionable mutation, I believe these patients are best served with a targeted agent, and in this case would be a combination of dabrafenib and trametinib”
Dr Raffaele Califano, The Christie and University Hospital of South Manchester
Select the menu within the video to enable you to skip between sections.
BRAF+, v-raf murine sarcoma viral oncogene homolog B1 positive; NSCLC, non-small cell lung cancer.
Indication: Tafinlar in combination with Mekinist is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.1,2
- Tafinlar (dabrafenib) GB Summary of Product Characteristics.
- Mekinist (trametinib) GB Summary of Product Characteristics.